Tissue expression of LC3B autophagy marker as a potential biomarker of prostate cancer recurrence after treatment with high-intensity focused ultrasound (pilot study)

E. S. Voronina, R. N. Fomkin, A. Bucharskaya, T. V. Palatova, G. Maslyakova, O. Fomkina
{"title":"Tissue expression of LC3B autophagy marker as a potential biomarker of prostate cancer recurrence after treatment with high-intensity focused ultrasound (pilot study)","authors":"E. S. Voronina, R. N. Fomkin, A. Bucharskaya, T. V. Palatova, G. Maslyakova, O. Fomkina","doi":"10.17650/1726-9776-2023-19-2-47-55","DOIUrl":null,"url":null,"abstract":"Background. The role of autophagy markers in prostate tumor recurrence has not been sufficiently investigated. We hypothesized that autophagy activation may be one mechanism by which prostate cancer cells survive exposure to high-intensity focused ultrasound (HIFU).Aim. To compare tissue expression of autophagic LC3B marker in prostate biopsies before and after treatment of localized prostate cancer by HIFU ablation.Materials and methods. 45 patients with localized morphologically confirmed prostate cancer were examined: group 1 – 25 patients of 65.6 ± 8.4 years without signs of recurrence or progression of the disease; group 2 – 20 patients of 67.5 ± 7.9 years with tumor recurrence proven during morphological examination. Immunohistochemical examination was performed by streptavidin-biotin method. In all cases, Anti-LC3B antibody ab48394 was used. The reaction results were quantified using the Histochemical score (Hs) system.Results. Prior to treatment, all patients of group 1 showed moderate cytoplasmic expression (Hs = 111 [111; 115]) of antibodies against LC3B in prostate adenocarcinoma cells, 5 % of patients – weak cytoplasmic expression in muscle connective stromal cells (Hs = 47 [43; 50]), 10 % of patients – weak positive LC3B reaction in the vessel wall (Hs = 28 [20; 35]). After treatment, the expression of LC3B in adenocarcinoma cells became negative, in the cytoplasm of muscle connective stromal cells weak (Hs = 75 [67.5; 80.0]), in the endothelium of the vascular wall even weaker (Hs = 55 [45.5; 60.0]) (p <0.001). Prior to treatment in group 2, LC3B expression in tumor tissue was moderate in 89 % of patients (Hs = 151.5 [137.5; 160.0]), weak in muscle connective stromal cells in 12 % of patients (Hs = 44 [35; 51.5]), and weak in the vascular wall in 5 % of patients (Hs = 30 [25; 35]). After treatment, LC3B expression in adenocarcinoma cells became pronounced (Hs = 260 [250; 285]), in muscle connective stromal cells – moderate (Hs = 118 [100; 130]), in the vascular wall – weak (Hs = 45 [30; 55]) (p <0.001). There was a significant correlation between tumor recurrence and LC3B overexpression (r = 0.51; p <0.001).Conclusion. The development of prostate cancer recurrence is associated with increased expression of autophagic LC3B protein. Increased LC3B expression, which is interpreted as evidence of autophagy activation and correlates with the risk of disease progression, is used by the tumor as an oncogenic advantage.","PeriodicalId":216890,"journal":{"name":"Cancer Urology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2023-19-2-47-55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. The role of autophagy markers in prostate tumor recurrence has not been sufficiently investigated. We hypothesized that autophagy activation may be one mechanism by which prostate cancer cells survive exposure to high-intensity focused ultrasound (HIFU).Aim. To compare tissue expression of autophagic LC3B marker in prostate biopsies before and after treatment of localized prostate cancer by HIFU ablation.Materials and methods. 45 patients with localized morphologically confirmed prostate cancer were examined: group 1 – 25 patients of 65.6 ± 8.4 years without signs of recurrence or progression of the disease; group 2 – 20 patients of 67.5 ± 7.9 years with tumor recurrence proven during morphological examination. Immunohistochemical examination was performed by streptavidin-biotin method. In all cases, Anti-LC3B antibody ab48394 was used. The reaction results were quantified using the Histochemical score (Hs) system.Results. Prior to treatment, all patients of group 1 showed moderate cytoplasmic expression (Hs = 111 [111; 115]) of antibodies against LC3B in prostate adenocarcinoma cells, 5 % of patients – weak cytoplasmic expression in muscle connective stromal cells (Hs = 47 [43; 50]), 10 % of patients – weak positive LC3B reaction in the vessel wall (Hs = 28 [20; 35]). After treatment, the expression of LC3B in adenocarcinoma cells became negative, in the cytoplasm of muscle connective stromal cells weak (Hs = 75 [67.5; 80.0]), in the endothelium of the vascular wall even weaker (Hs = 55 [45.5; 60.0]) (p <0.001). Prior to treatment in group 2, LC3B expression in tumor tissue was moderate in 89 % of patients (Hs = 151.5 [137.5; 160.0]), weak in muscle connective stromal cells in 12 % of patients (Hs = 44 [35; 51.5]), and weak in the vascular wall in 5 % of patients (Hs = 30 [25; 35]). After treatment, LC3B expression in adenocarcinoma cells became pronounced (Hs = 260 [250; 285]), in muscle connective stromal cells – moderate (Hs = 118 [100; 130]), in the vascular wall – weak (Hs = 45 [30; 55]) (p <0.001). There was a significant correlation between tumor recurrence and LC3B overexpression (r = 0.51; p <0.001).Conclusion. The development of prostate cancer recurrence is associated with increased expression of autophagic LC3B protein. Increased LC3B expression, which is interpreted as evidence of autophagy activation and correlates with the risk of disease progression, is used by the tumor as an oncogenic advantage.
LC3B自噬标志物作为前列腺癌高强度聚焦超声治疗后复发潜在生物标志物的组织表达(初步研究)
背景。自噬标志物在前列腺肿瘤复发中的作用尚未得到充分的研究。我们假设自噬激活可能是前列腺癌细胞暴露于高强度聚焦超声(HIFU)下存活的机制之一。目的比较HIFU消融治疗局限性前列腺癌前后前列腺活检组织中自噬LC3B标志物的表达。材料和方法。本文对45例经局部形态学证实的前列腺癌患者进行了检查:1 - 25例患者(65.6±8.4年)无复发或疾病进展迹象;2 - 20例经形态学检查证实肿瘤复发的患者,年龄67.5±7.9岁。采用链霉亲和素-生物素法进行免疫组化检查。所有病例均使用抗lc3b抗体ab48394。采用组织化学评分(Hs)系统对反应结果进行量化。治疗前,1组患者均为中度细胞质表达(Hs = 111 [111;115]), 5%的患者-肌结缔组织间质细胞中LC3B抗体表达弱(Hs = 47 [43;50]), 10%的患者-血管壁LC3B反应弱阳性(Hs = 28 [20;35])。经治疗后,LC3B在腺癌细胞中的表达变为阴性,在肌结缔组织基质细胞细胞质中的表达较弱(Hs = 75 [67.5;[80.0]),在血管壁内皮细胞更弱(Hs = 55 [45.5;60.0]) (p <0.001)。2组治疗前,89%的患者肿瘤组织LC3B表达为中度(Hs = 151.5 [137.5;160.0]), 12%的患者肌肉结缔组织间质细胞较弱(Hs = 44 [35;51.5]), 5%的患者血管壁弱(Hs = 30 [25;35])。治疗后,LC3B在腺癌细胞中的表达变得明显(Hs = 260 [250;285]),肌肉结缔组织基质细胞-中度(Hs = 118 [100;130]),在血管壁-弱(Hs = 45 [30;55]) (p <0.001)。LC3B过表达与肿瘤复发有显著相关性(r = 0.51;.Conclusion p < 0.001)。前列腺癌复发的发生与自噬性LC3B蛋白表达增加有关。LC3B表达的增加被解释为自噬激活的证据,与疾病进展的风险相关,被肿瘤用作致癌优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信